Zevra Therapeutics partners with GeneDx to launch genetic testing for NPC in U.S.

Zevra Therapeutics partners with GeneDx to launch genetic testing for NPC in U.S.
Zevra Therapeutics launches NPC program

Zevra Therapeutics has partnered with GeneDx to introduce a sponsored genetic testing program for eligible patients in the U.S. suspected of having Niemann-Pick disease type C (NPC).

The initiative is aimed at improving early diagnosis and access to advanced testing for individuals facing this rare and challenging disorder. According to Zevra Therapeutics, the collaboration will expand availability of testing resources to better support patients and caregivers affected by NPC across the U.S. healthcare system.

The new initiative underscores Zevra Therapeutics’ commitment to advancing rare disease care, complementing the company’s continued efforts to expand its presence in the biopharmaceutical sector, as highlighted during its recent Nasdaq bell ceremony marking key milestones in its growth trajectory.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.